Shopping Cart 0
Cart Subtotal
AED 0

Alder Biopharmaceuticals Inc (ALDR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alder's clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The company's eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.

Alder Biopharmaceuticals Inc (ALDR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Alder Biopharma Raises USD 38 Million In Series D Financing 11

Licensing Agreements 13

Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13

Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14

Equity Offering 15

Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15

Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16

Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18

Alder BioPharma Raises USD230 Million in Public Offering of Shares 20

Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22

Alder Biopharma Raises USD88.8 Million in IPO 24

Debt Offering 26

Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26

Alder Biopharmaceuticals Inc-Key Competitors 28

Alder Biopharmaceuticals Inc-Key Employees 29

Alder Biopharmaceuticals Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31

Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32

May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33

Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34

Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36

Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37

Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39

Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41

Corporate Communications 43

Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43

Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44

Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45

Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46

Product News 47

03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47

Clinical Trials 48

Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48

Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49

Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alder Biopharma Raises USD 38 Million In Series D Financing 11

Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13

Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14

Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15

Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16

Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18

Alder BioPharma Raises USD230 Million in Public Offering of Shares 20

Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22

Alder Biopharma Raises USD88.8 Million in IPO 24

Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26

Alder Biopharmaceuticals Inc, Key Competitors 28

Alder Biopharmaceuticals Inc, Key Employees 29

Alder Biopharmaceuticals Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alder Biopharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Alder Biopharmaceuticals Inc (Alder) is a biopharmaceutical company which develops, produces and markets monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases. The company uses technologies such as the antibody selection system and novel mab xpress antibody production system. Its pipeline products include clazakizumab and eptinezumab. Alder's clazakizumab is a novel monoclonal antibody used for the treatment of rheumatoid arthritis and psoriatic arthritis. The company's eptinezumab is an investigational product candidate for migraine prevention treatment for patients with chronic and frequent episodic migraine. Alder is headquartered in Bothell, Washington, the US.

Alder Biopharmaceuticals Inc (ALDR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Alder Biopharma Raises USD 38 Million In Series D Financing 11

Licensing Agreements 13

Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13

Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14

Equity Offering 15

Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15

Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16

Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18

Alder BioPharma Raises USD230 Million in Public Offering of Shares 20

Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22

Alder Biopharma Raises USD88.8 Million in IPO 24

Debt Offering 26

Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26

Alder Biopharmaceuticals Inc-Key Competitors 28

Alder Biopharmaceuticals Inc-Key Employees 29

Alder Biopharmaceuticals Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 05, 2018: Alder BioPharmaceuticals reports third quarter 2018 financial and operating results 31

Aug 07, 2018: Alder BioPharmaceuticals reports second quarter 2018 financial and operating results 32

May 08, 2018: Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results 33

Feb 26, 2018: Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results 34

Nov 07, 2017: Alder BioPharmaceuticals Announces Third Quarter 2017 Financial and Operating Results 36

Aug 08, 2017: Alder BioPharmaceuticals Announces Second Quarter 2017 Financial and Operating Results 37

Apr 27, 2017: Alder BioPharmaceuticals Announces First Quarter 2017 Financial and Operating Results 39

Feb 23, 2017: Alder BioPharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial and Operating Results 41

Corporate Communications 43

Apr 26, 2018: Alder BioPharmaceuticals Appoints Jeremy Green to its Board of Directors 43

Apr 16, 2018: Alder BioPharmaceuticals Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer 44

Mar 20, 2018: Alder BioPharmaceuticals Appoints Paul B. Cleveland as Interim President and Chief Executive Officer 45

Apr 04, 2017: Alder BioPharmaceuticals Appoints Wendy L. Yarno to its Board of Directors 46

Product News 47

03/06/2017: Alder BioPharmaceuticals Announces Presentations at 69th Annual American Academy of Neurology Meeting Supporting Development of Eptinezumab for Migraine Prevention 47

Clinical Trials 48

Jun 07, 2017: Alder to Present Migraine Prevention Data for Eptinezumab at 59th Annual Scientific Meeting of the American Headache Society 48

Apr 28, 2017: Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting 49

Apr 24, 2017: Alder BioPharmaceuticals Presents Additional Data from Eptinezumab Development Program at 69th Annual American Academy of Neurology Meeting 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alder Biopharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Alder Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Alder Biopharma Raises USD 38 Million In Series D Financing 11

Teva Pharma Enters into Licensing Agreement with Alder Biopharma 13

Vitaeris Enters into Licensing Agreement with Alder BioPharma for Clazakizumab 14

Alder Biopharma Raises USD100 Million in Private Placement of Preferred Stock 15

Alder BioPharma Raises USD172.5 Million in Public Offering of Shares 16

Alder BioPharma Raises USD143.8 Million in Public Offering of Shares 18

Alder BioPharma Raises USD230 Million in Public Offering of Shares 20

Alder BioPharma Raises USD203.6 Million in Public Offering of Shares 22

Alder Biopharma Raises USD88.8 Million in IPO 24

Alder Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of 2.5% Notes Due 2025 for USD287.5 Million 26

Alder Biopharmaceuticals Inc, Key Competitors 28

Alder Biopharmaceuticals Inc, Key Employees 29

Alder Biopharmaceuticals Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alder Biopharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.